|
AR073380A1
(es)
|
2008-09-25 |
2010-11-03 |
Takeda Pharmaceutical |
Composicion farmaceutica solida. comprimido multicapa
|
|
EP2351743A4
(en)
|
2008-10-27 |
2012-05-09 |
Takeda Pharmaceutical |
BICYCLIC COMPOUND
|
|
EP2371826A4
(en)
|
2008-12-29 |
2012-06-27 |
Takeda Pharmaceutical |
NEW CONNECTION WITH CONDENSED RINGS AND ITS USE
|
|
EP2440541A1
(en)
|
2009-06-09 |
2012-04-18 |
Takeda Pharmaceutical Company Limited |
Novel fused cyclic compound and use thereof
|
|
MX2012001284A
(es)
|
2009-07-28 |
2012-03-26 |
Takeda Pharmaceutical |
Tableta.
|
|
ES2835553T3
(es)
|
2009-08-10 |
2021-06-22 |
Biosplice Therapeutics Inc |
Inhibidores de indazol de la vía de señalización de Wnt y sus usos terapéuticos
|
|
US20110112158A1
(en)
*
|
2009-11-11 |
2011-05-12 |
David Robert Bolin |
Benzisoxazole analogs as glycogen synthase activators
|
|
CN102821607B
(zh)
|
2009-12-21 |
2014-12-17 |
萨穆梅德有限公司 |
1H-吡唑并[3,4-b]吡啶及其治疗应用
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
MA34245B1
(fr)
|
2010-04-27 |
2013-05-02 |
Takeda Pharmaceutcal Company Ltd |
Dérivés de composés bicycliques et leur utilisation en tant qu'inhibiteurs de l'acc.
|
|
EA022094B1
(ru)
|
2010-06-16 |
2015-10-30 |
Такеда Фармасьютикал Компани Лимитед |
Кристаллическая форма амидного соединения
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
EP2617726A4
(en)
|
2010-09-17 |
2014-05-14 |
Takeda Pharmaceutical |
DIABETES THERAPEUTIC
|
|
EA201390794A1
(ru)
|
2010-11-30 |
2013-11-29 |
Такеда Фармасьютикал Компани Лимитед |
Бициклическое соединение
|
|
BR112013020634A2
(pt)
|
2011-02-17 |
2016-10-25 |
Takeda Pharmaceutical |
método para produzir uma forma opticamente ativa de um composto, sal, complexo de rutênio, composto, e, cristal
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
HRP20190281T1
(hr)
|
2011-09-14 |
2019-05-31 |
Samumed, Llc |
Indazol-3-karboksamidi i njihova uporaba kao inhibitora signalizacijskog puta wnt/b-katenin
|
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
EP2772485A4
(en)
|
2011-10-24 |
2015-06-10 |
Takeda Pharmaceutical |
BICYCLIC CONNECTION
|
|
EP2802571A1
(en)
|
2012-01-12 |
2014-11-19 |
Takeda Pharmaceutical Company Limited |
Benzimidazole derivatives as mch receptor antagonists
|
|
EP2816032A4
(en)
|
2012-02-13 |
2015-09-30 |
Takeda Pharmaceutical |
AROMATIC RING CONNECTION
|
|
US9382188B2
(en)
|
2012-02-13 |
2016-07-05 |
Takeda Pharmaceutical Company Limited |
Aromatic ring compound
|
|
US20150011549A1
(en)
|
2012-02-15 |
2015-01-08 |
Takeda Pharmaceutical Company Limited |
Tablet
|
|
CN104254525B
(zh)
|
2012-02-24 |
2016-05-25 |
武田药品工业株式会社 |
芳环化合物
|
|
CN104350040B
(zh)
|
2012-03-29 |
2016-06-01 |
武田药品工业株式会社 |
芳环化合物
|
|
PH12017500997A1
(en)
|
2012-04-04 |
2018-02-19 |
Samumed Llc |
Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
|
|
PL2770994T3
(pl)
|
2012-05-04 |
2020-03-31 |
Samumed, Llc |
1H-Pirazolo[3,4-b]pirydyny i ich zastosowania terapeutyczne
|
|
US9440987B2
(en)
|
2012-05-10 |
2016-09-13 |
Takeda Pharmaceutical Company Limited |
Aromatic ring compound
|
|
US9505772B2
(en)
|
2012-05-10 |
2016-11-29 |
Takeda Pharmaceutical Company Limited |
Aromatic ring compound
|
|
CN104519874B
(zh)
|
2012-06-05 |
2018-08-03 |
武田药品工业株式会社 |
固体制剂
|
|
JP2015127299A
(ja)
|
2012-07-19 |
2015-07-09 |
武田薬品工業株式会社 |
固形製剤
|
|
EP2943198B1
(en)
|
2013-01-08 |
2019-07-17 |
Samumed, LLC |
3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
|
|
US9605000B2
(en)
|
2013-03-14 |
2017-03-28 |
Takeda Pharmaceutical Company Limited |
Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
|
|
US10005720B2
(en)
|
2013-04-05 |
2018-06-26 |
North Carolina Central University |
Compounds useful for the treatment of metabolic disorders and synthesis of the same
|
|
TW201536767A
(zh)
|
2013-07-09 |
2015-10-01 |
Takeda Pharmaceutical |
雜環化合物
|
|
HRP20181011T1
(hr)
|
2013-08-09 |
2018-08-24 |
Takeda Pharmaceutical Company Limited |
Aromatski spoj
|
|
JO3442B1
(ar)
|
2013-10-07 |
2019-10-20 |
Takeda Pharmaceuticals Co |
مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
|
|
US9428470B2
(en)
|
2014-02-13 |
2016-08-30 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
|
US9346776B2
(en)
|
2014-02-13 |
2016-05-24 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic compound
|
|
CN104151216B
(zh)
*
|
2014-08-22 |
2016-08-17 |
山东铂源药业有限公司 |
一种拉帕替尼侧链的合成方法
|
|
WO2016040193A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
|
WO2016040184A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
|
WO2016040181A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
|
WO2016040180A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
|
WO2016040182A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
|
|
WO2016040190A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
|
WO2016040185A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
|
|
WO2016040188A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
|
US10221172B2
(en)
|
2015-01-13 |
2019-03-05 |
Vanderbilt University |
Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
|
|
WO2017024010A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
|
US10206909B2
(en)
|
2015-08-03 |
2019-02-19 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
|
WO2017024015A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
WO2017023975A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
|
WO2017023984A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
|
WO2017023986A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
|
|
US10519169B2
(en)
|
2015-08-03 |
2019-12-31 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
|
US10166218B2
(en)
|
2015-08-03 |
2019-01-01 |
Samumed, Llc |
3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
|
US10350199B2
(en)
|
2015-08-03 |
2019-07-16 |
Samumed, Llc |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
|
US10285983B2
(en)
|
2015-08-03 |
2019-05-14 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
|
|
WO2017023972A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
WO2017023987A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
|
WO2017023993A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
US10188634B2
(en)
|
2015-08-03 |
2019-01-29 |
Samumed, Llc |
3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
|
US10285982B2
(en)
|
2015-08-03 |
2019-05-14 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
|
US10392383B2
(en)
|
2015-08-03 |
2019-08-27 |
Samumed, Llc |
3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
US10231956B2
(en)
|
2015-08-03 |
2019-03-19 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
|
JP6913076B2
(ja)
|
2015-08-07 |
2021-08-04 |
バイエル・クロップサイエンス・アクチェンゲゼルシャフト |
有害生物防除剤としての2−(ヘタ)アリール−置換縮合ヘテロ環誘導体
|
|
KR20180080262A
(ko)
|
2015-11-06 |
2018-07-11 |
사뮤메드, 엘엘씨 |
골관절염의 치료
|
|
GB201604970D0
(en)
|
2016-03-23 |
2016-05-04 |
Syngenta Participations Ag |
Improvements in or relating to organic compounds
|
|
AR108325A1
(es)
|
2016-04-27 |
2018-08-08 |
Samumed Llc |
Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
|
|
ES2933109T3
(es)
|
2016-06-01 |
2023-02-02 |
Biosplice Therapeutics Inc |
Proceso para preparar N-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida
|
|
CN110709082A
(zh)
|
2016-10-21 |
2020-01-17 |
萨穆梅德有限公司 |
吲唑-3-甲酰胺的使用方法及其作为Wnt/β-连环蛋白信号传导途径抑制剂的用途
|
|
KR102558716B1
(ko)
|
2016-11-07 |
2023-07-21 |
사뮤메드, 엘엘씨 |
단일-투여량, 즉시-사용가능한 주사용 제제
|
|
JOP20180029A1
(ar)
|
2017-03-30 |
2019-01-30 |
Takeda Pharmaceuticals Co |
مركب حلقي غير متجانس
|
|
CN110719903A
(zh)
|
2017-03-31 |
2020-01-21 |
武田药品工业株式会社 |
芳族环化合物
|
|
AR111199A1
(es)
|
2017-03-31 |
2019-06-12 |
Takeda Pharmaceuticals Co |
Compuesto aromático agonista de gpr40
|
|
JOP20180028A1
(ar)
|
2017-03-31 |
2019-01-30 |
Takeda Pharmaceuticals Co |
مركب ببتيد
|
|
CN110117278B
(zh)
*
|
2018-02-07 |
2022-07-19 |
石家庄以岭药业股份有限公司 |
烷氧基苯并五元(六元)杂环胺类化合物及其药物用途
|
|
EA202092269A1
(ru)
|
2018-03-23 |
2020-12-14 |
Кармот Терапьютикс, Инк. |
Модуляторы сопряженных с g-белком рецепторов
|
|
TW202024028A
(zh)
|
2018-08-27 |
2020-07-01 |
日商思可海雅藥品股份有限公司 |
苯甲酸酯化合物
|
|
US12122815B2
(en)
|
2018-09-24 |
2024-10-22 |
Takeda Pharmaceutical Company Limited |
GIP receptor agonist peptide compounds and uses thereof
|
|
JP7511548B2
(ja)
|
2018-09-24 |
2024-07-05 |
武田薬品工業株式会社 |
Gip受容体アゴニストペプチド化合物及びその使用
|
|
PH12022552056A1
(en)
|
2020-02-07 |
2024-02-12 |
Gasherbrum Bio Inc |
Heterocyclic glp-1 agonists
|
|
BR112022019114A2
(pt)
|
2020-03-25 |
2023-02-14 |
Takeda Pharmaceuticals Co |
Dosagem qd de compostos peptídicos agonistas do receptor de gip e usos dos mesmos
|
|
PE20221727A1
(es)
|
2020-03-25 |
2022-11-04 |
Takeda Pharmaceuticals Co |
Dosificacion qw de compuestos peptidicos agonistas del receptor de gip y sus usos
|
|
CN112062754B
(zh)
*
|
2020-09-24 |
2022-06-21 |
深圳市华先医药科技有限公司 |
一种合成Dorzagliatin的中间体的制备方法
|
|
CN114369097B
(zh)
*
|
2020-10-15 |
2023-07-14 |
山东轩竹医药科技有限公司 |
杂芳环类AhR抑制剂
|
|
CN112300028B
(zh)
*
|
2020-10-27 |
2022-03-11 |
无锡双启科技有限公司 |
一种2-氨基-3-甲氧基-5-溴苯腈的制备方法
|
|
US12152018B2
(en)
|
2021-01-08 |
2024-11-26 |
Ifm Due, Inc. |
Compounds and compositions for treating conditions associated with STING activity
|
|
PE20240890A1
(es)
|
2021-05-13 |
2024-04-24 |
Carmot Therapeutics Inc |
Moduladores de los receptores acoplados a proteinas g
|
|
EP4488275A4
(en)
|
2022-03-04 |
2025-07-23 |
Shanghai Yingli Pharm Co Ltd |
COMPOUND CONTAINING A FIVE-MEMBERED HETEROAROMATIC RING STRUCTURE, PHARMACEUTICAL COMPOSITION AND USE THEREOF
|
|
CN119137124A
(zh)
|
2022-03-09 |
2024-12-13 |
加舒布鲁姆生物公司 |
杂环glp-1激动剂
|
|
JP2025510741A
(ja)
|
2022-03-21 |
2025-04-15 |
ガシャーブラム・バイオ・インコーポレイテッド |
ヘテロ環式glp-1アゴニスト
|
|
CN119255988A
(zh)
|
2022-04-14 |
2025-01-03 |
加舒布鲁姆生物公司 |
杂环glp-1激动剂
|
|
EP4622643A1
(en)
*
|
2022-11-22 |
2025-10-01 |
Maze Therapeutics, Inc. |
Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof
|
|
WO2024125602A1
(en)
|
2022-12-15 |
2024-06-20 |
Gasherbrum Bio, Inc. |
Salts and solid forms of a compound having glp-1 agonist activity
|
|
WO2024131869A1
(en)
|
2022-12-22 |
2024-06-27 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
EP4638455A1
(en)
|
2022-12-22 |
2025-10-29 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
CN120957993A
(zh)
|
2023-02-16 |
2025-11-14 |
加舒布鲁姆生物公司 |
杂环glp-1激动剂
|
|
WO2025006921A1
(en)
|
2023-06-30 |
2025-01-02 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
WO2025015268A1
(en)
|
2023-07-13 |
2025-01-16 |
Aconcagua Bio, Inc. |
Modulators of calcitonin receptor and/or amylin receptor activity
|
|
TW202519220A
(zh)
|
2023-07-13 |
2025-05-16 |
美商雅空嘉閣生物公司 |
化合物、組合物及方法
|
|
WO2025045208A1
(en)
|
2023-08-31 |
2025-03-06 |
Gasherbrum Bio, Inc. |
Heteroaryl-heterocycloalkyl-based glp-1 agonists
|
|
WO2025137307A1
(en)
|
2023-12-20 |
2025-06-26 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
WO2025154021A1
(en)
|
2024-01-19 |
2025-07-24 |
Takeda Pharmaceutical Company Limited |
Improved gip receptor agonist peptide compounds and uses thereof
|
|
WO2025154020A1
(en)
|
2024-01-19 |
2025-07-24 |
Takeda Pharmaceutical Company Limited |
Improved gip receptor agonist peptide compounds and uses thereof
|
|
WO2025171340A1
(en)
|
2024-02-08 |
2025-08-14 |
Aconcagua Bio, Inc. |
The treatment of calcitonin- and/or amylin-receptor associated conditions
|
|
WO2025171341A2
(en)
|
2024-02-08 |
2025-08-14 |
Aconcagua Bio, Inc. |
Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
|